We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Merck & Co. likely expected big numbers from Eisai’s Lenvima when it agreed in March to fork over $5.8 billion to share rights to the drug. And those numbers are rolling in.